Trimi vs Arc-1
Two GLP-1 desks, one scoreboard. We put Trimi and Arc-1 head-to-head on the published Brief Score — the same six factors, scored the same way.
The verdict
Trimi takes this head-to-head.
Trimi scores 89 to 64 on our six-factor Brief Score — A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.
That doesn't make Arc-1 a bad call — it's best for patients seeking per-dose compounded glp-1 without subscriptions. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Trimi | Arc-1 | |
|---|---|---|
| Brief Score | 89/100 (B+) | 64/100 (C) |
| Semaglutide | $196/mo | From $200/mo (compounded) |
| Tirzepatide | $296/mo | From $200/mo (compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Trimi: Membership rate held flat this cycle — both molecules disclosed up front, no first-month teaser.
Arc-1: New to the tracker on 1 August 2026. The published line reads From $200/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.